| 1 |
33191904 | Relative contributions of metabolic enzymes to systemic elimination can be estimated from clinical DDI studies: Validation using an in silico approach. | 2021 Mar |
1 |
| 2 |
33088647 | Severe hypoglycemia caused by a small dose of repaglinide and concurrent use of nilotinib and febuxostat in a patient with type 2 diabetes. | 2020 Oct |
1 |
| 3 |
29901213 | PBPK Modeling Strategy for Predicting Complex Drug Interactions of Letermovir as a Perpetrator in Support of Product Labeling. | 2019 Feb |
1 |
| 4 |
27599706 | Physiologically Based Pharmacokinetic Modeling to Predict Drug-Drug Interactions with Efavirenz Involving Simultaneous Inducing and Inhibitory Effects on Cytochromes. | 2017 Apr |
1 |
| 5 |
28238899 | Estimation of the Contribution of CYP2C8 and CYP3A4 in Repaglinide Metabolism by Human Liver Microsomes Under Various Buffer Conditions. | 2017 Sep |
2 |
| 6 |
28479356 | Quantitative Analysis of Complex Drug-Drug Interactions Between Repaglinide and Cyclosporin A/Gemfibrozil Using Physiologically Based Pharmacokinetic Models With In Vitro Transporter/Enzyme Inhibition Data. | 2017 Sep |
2 |
| 7 |
26296069 | Physiologically based pharmacokinetics model predicts the lack of inhibition by repaglinide on the metabolism of pioglitazone. | 2015 Dec |
1 |
| 8 |
24971633 | Glucuronidation converts clopidogrel to a strong time-dependent inhibitor of CYP2C8: a phase II metabolite as a perpetrator of drug-drug interactions. | 2014 Oct |
1 |
| 9 |
23393219 | Quantitative prediction of repaglinide-rifampicin complex drug interactions using dynamic and static mechanistic models: delineating differential CYP3A4 induction and OATP1B1 inhibition potential of rifampicin. | 2013 May |
2 |
| 10 |
23807564 | PXR polymorphisms and their impact on pharmacokinetics/pharmacodynamics of repaglinide in healthy Chinese volunteers. | 2013 Nov |
1 |
| 11 |
22451699 | A comprehensive assessment of repaglinide metabolic pathways: impact of choice of in vitro system and relative enzyme contribution to in vitro clearance. | 2012 Jul |
1 |
| 12 |
20523106 | CYP3A4 genetic polymorphism influences repaglinide's pharmacokinetics. | 2010 |
8 |
| 13 |
16447051 | Pioglitazone, an in vitro inhibitor of CYP2C8 and CYP3A4, does not increase the plasma concentrations of the CYP2C8 and CYP3A4 substrate repaglinide. | 2006 Mar |
1 |
| 14 |
16513447 | Telithromycin, but not montelukast, increases the plasma concentrations and effects of the cytochrome P450 3A4 and 2C8 substrate repaglinide. | 2006 Mar |
3 |
| 15 |
16176562 | Metabolism of repaglinide by CYP2C8 and CYP3A4 in vitro: effect of fibrates and rifampicin. | 2005 Oct |
5 |
| 16 |
16198658 | Cyclosporine markedly raises the plasma concentrations of repaglinide. | 2005 Oct |
1 |
| 17 |
15099124 | Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus. | 2004 |
1 |
| 18 |
12817528 | Influence of drugs interacting with CYP3A4 on the pharmacokinetics, pharmacodynamics, and safety of the prandial glucose regulator repaglinide. | 2003 Jun |
5 |
| 19 |
12919179 | CYP2C8 and CYP3A4 are the principal enzymes involved in the human in vitro biotransformation of the insulin secretagogue repaglinide. | 2003 Sep |
4 |
| 20 |
12405866 | Interactions between antiretroviral drugs and drugs used for the therapy of the metabolic complications encountered during HIV infection. | 2002 |
1 |